Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (Advances in Therapy, (2020), 37, 9, (4033-4042), 10.1007/s12325-020-01449-0)

Pietro Lampertico*, Stefan Mauss, Marcello Persico, Stephen T. Barclay, Steven Marx, Kristina Lohmann, Mark Bondin, Zhen Zhen Zhang, Fiona Marra, Pamela S. Belperio, Heiner Wedemeyer, Steven Flamm

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (Advances in Therapy, (2020), 37, 9, (4033-4042), 10.1007/s12325-020-01449-0)'. Together they form a unique fingerprint.

INIS

Pharmacology, Toxicology and Pharmaceutical Science